Resumo

CRUZ-GUISBERT, J R. Survival analysis of patients with breast cancer: in the Hospital Seguro Social Universitario, term 2000 to 2016. Cuad. - Hosp. Clín. [online]. 2019, vol.60, n.2, pp.39-45. ISSN 1562-6776.

Abstract OBJECTIVE_: To determine the survival ofpatients with breast cancer in the University Social Security Hospital, from term 2000 to 2016 METHOD: Mixed cohort study RESULTS: Survival of patients with breast cancer, had an average survival time of 104 months (8,6 years), in Hormonal cases (+) who received treatment with Exemestane, after Adriamycin and Cyclophosphamide survival time was 99,5 months (IC 83,2 -115,78). In contrast, in patients with breast cancer Herb New (-) treated with Trastuzumab, after receiving Adriamycin and Cyclophosphamide was 103,28 months (IC 86,54 -120,024). The median survival time was 104,13 months. The only factor that predicts the survival of patients with breast cancer, in this study was the histological type (p = 0,026), with a relative risk of 17,6. CONCLUSIONS: The survival of patients with breast cancer, treated at the University Social Security Hospital, from the term 2000 to 2016, was 8.6 years, a result equivalent to those reported in the literature.

Palavras-chave : Survival; Breast cancer.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )